Digital healthcare company iRhythm Holdings, Inc. (NASDAQ:IRTC) on Thursday agreed to acquire Vital Connect, Inc., a privately held developer of wearable biosensor technology.
iRhythm Agrees To Acquire VitalConnect for $287.5 Million
The transaction, valued at approximately $287.5 million, aims to significantly broaden iRhythm’s footprint in ambulatory cardiac monitoring and advanced multi-vitals tracking.
The total purchase price consists of roughly $237.5 million in cash, sourced directly from existing funds on iRhythm’s balance sheet, alongside about $50 million in shares.
To support VitalConnect through the transition, iRhythm will also supply interim working capital financing.
The initial funding starts at $10 million, with additional increments available up to a maximum aggregate of $30 million.
Acquisition Broadens Cardiac Monitoring and Multi-Vitals Capabilities
Strategically, the acquisition integrates VitalConnect’s FDA-cleared technology into iRhythm’s portfolio. This platform features a wide range of cardiac monitoring modalities and multi-vitals tracking capabilities designed for both remote care and hospital settings.
The management expects the buyout to strengthen the company’s long-term growth profile. The integration is projected to become accretive to iRhythm’s overall revenue growth rate beginning in 2027.
The efficiency will help finance future growth investments while maintaining the company’s previously stated adjusted EBITDA margin target of 15% in 2027.
Q2 Performance
iRhythm reported second quarter adjusted earnings of 58 cents. Sales jumped 20.1% year over year to $224.172 million, beating the consensus of $219.324 million.
The company’s quarterly performance demonstrated robust volume-led revenue growth and expanded margins, with continued momentum across cardiology, primary care, innovative channels, and international markets.
Gross profit was $163.2 million, up 22.8% year over year, while gross margin was 72.8%, a 160-basis point improvement.
The increase in gross profit was primarily due to increased volume of Zio services. The increase in gross margin was primarily driven by continued operational efficiencies, product mix, and scale benefits from higher volumes.
iRhythm Raises Fiscal 2026 Sales Guidance
iRhythm raised its fiscal 2026 sales guidance from $875 million-$885 million to $880 million-$890 million versus the consensus of $881.129 million.
William Blair on Friday wrote, “We expect the company will integrate VitalPatch into the existing Zio Suite software and the company will look to expand using the access to new vitals and other VitalConnect IP.”
“In sum, we think this was a good decision from management as this deal will allow it to further accelerate its top line alongside an eventual MCT launch and bolster its margin profile as the new product ramps up,” analyst Brandon Vazquez wrote.
IRTC Price Action: iRhythm Holdings shares were up 3.68% at $132.84 at the time of publication on Friday, according to Benzinga Pro data.
Photo: Shutterstock
